Overview

TREXIMET (Formerly Known as TREXIMA) for the Acute Treatment of Probable Migraine (ICHD-II 1.6.1)

Status:
Completed
Trial end date:
2008-02-01
Target enrollment:
Participant gender:
Summary
This study was designed to determine the efficacy and tolerability of TREXIMET (formerly known as TREXIMA) compared to placebo for the acute treatment of probable migraine, a sub-type of migraine.
Phase:
Phase 3
Details
Lead Sponsor:
GlaxoSmithKline
Treatments:
Naproxen
Sumatriptan